secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2023-08-21T23:59:59+00:00
Accession:  0001714899-23-000131
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali amends Biogen pacts; milestones unchanged, Biogen waives option rights
-----------------------------------------------------------------------------

- Amendment to LRRK2 Collaboration and ROFN agreements executed Aug 17, 2023.
- Milestone schedule revised but total eligible milestone value remains unchanged.
- Biogen waives option to second program and rights of first negotiation for two TV-enabled programs.
- Relates to prior announcements on June 5, 2023 (LRRK2) and April 12, 2023 (ATV:Aβ).
- Other terms of original agreements remain in full force per Denali.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489923000131/0001714899-23-000131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489923000131/dnli-20230817.htm
  HTML page:      https://secwatch.observer/filing/0001714899-23-000131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer